Evidence map›Paper›PMID 24556275›Full record

ReviewDrug and alcohol dependence2014

Toward empirical identification of a clinically meaningful indicator of treatment outcome: features of candidate indicators and evaluation of sensitivity to treatment effects and relationship to one year follow up cocaine use outcomes.

Kathleen M Carroll, Brian D Kiluk, Charla Nich, Elise E DeVito, Suzanne Decker, Donna LaPaglia, Dianne Duffey, Theresa A Babuscio, Samuel A Ball

Abstract readEvaluation StudyReview
In one paragraph

Review in Drug and alcohol dependence, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Characterizing cannabis use reduction and change in functioning during treatment: Initial steps on the path to new clinical endpoints.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022
    Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kathleen M CarrollDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States. Electronic address: kathleen.carroll@yale.edu.
Brian D KilukDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States.
Charla NichDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States.
Elise E DeVitoDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States.
Suzanne DeckerDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States; New England Mental Illness, Research Education and Clinical Center, VA Connecticut Healthcare System, United States.
Donna LaPagliaDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States.
Dianne DuffeyDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States.
Theresa A BabuscioDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States.
Samuel A BallDepartment of Psychiatry, Yale University School of Medicine, 950 Campbell Avenue, 151D, West Haven, CT 06516, United States; The APT Foundation, New Haven Connecticut, 1 Long Wharf, New Haven, CT 06511, United States.

Funding

TSF to enhance treatment of cocaine dependenceP50DA009241 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1994 to 2018
$40.5M
The National Drug Abuse Treatment Clinical Trials Network (U10)U10DA015831 · NIDA · MC LEAN HOSPITAL (BELMONT, MA) · PI CARROLL, KATHLEEN M., WEISS, ROGER D. · 2002 to 2015
$28.8M
CLINICAL TRIALS NETWORK: NEW ENGLAND NODEU10DA013038 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1999 to 2010
$17.3M
Computer-Based Training in Cognitve Behavioral TherapyR01DA015969 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 2002 to 2015
$2.8M
Computer-Based Training in Cognitve Behavioral TherapyR37DA015969 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 2003 to 2009
$2.6M
Yale BIRCWH Scholar Program on Women's Health and Addictive BehaviorsK12DA031050 · NIDA · YALE UNIVERSITY · PI MAZURE, CAROLYN M. · 2010 to 2014
$2.5M
Maximizing CBT's Efficacy with Medication &CMR01DA019078 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 2005 to 2009
$1.6M
NIDA NIH HHS K12 DA031050NIDA NIH HHS K12DA031050NIDA NIH HHS P50 DA009241NIDA NIH HHS P50-DA09241NIDA NIH HHS R01 DA015969NIDA NIH HHS R01 DA015969-09S1NIDA NIH HHS R01 DA019078NIDA NIH HHS R37 DA015969NIDA NIH HHS U10 DA013038NIDA NIH HHS U10 DA015831
6 · The paper itself

Abstract

backgroundSelection of an appropriate indictor of treatment response in clinical trials is complex, particularly for the various illicit drugs of abuse. Most widely used indicators have been selected based on expert group recommendation or convention rather than systematic empirical evaluation. Absence of an evidence-based, clinically meaningful index of treatment outcome hinders cross-study evaluations necessary for progress in addiction treatment science.

methodFifteen candidate indicators used in multiple clinical trials as well as some proposed recently are identified and discussed in terms of relative strengths and weaknesses (practicality, cost, verifiability, sensitivity to missing data). Using pooled data from five randomized controlled trials of cocaine dependence (N=434), the indicators were compared in terms of sensitivity to the effects of treatment and relationship to cocaine use and general functioning during follow-up.

resultsCommonly used outcome measures (percent negative urine screens; percent days of abstinence) performed relatively well in that they were sensitive to the effects of the therapies evaluated. Others, including complete abstinence and reduction in frequency of use, were less sensitive to effects of specific therapies and were very weakly related to cocaine use or functioning during follow-up. Indicators more strongly related to cocaine use during follow-up were those that reflected achievement of sustained periods of abstinence, particularly at the end of treatment.

conclusionsThese analyses did not demonstrate overwhelming superiority of any single indicator, but did identify several that performed particularly poorly. Candidates for elimination included retention, complete abstinence, and indicators of reduced frequency of cocaine use.

Indexed as

Empirical ResearchAnimalsClinical Trials as TopicCocaine-Related DisordersFollow-Up StudiesHumansQuality Indicators, Health CareTreatment OutcomeCocaine use disordersFollow-up studiesRandomized trialsTreatment outcome indicators

Identifiers

PMID24556275
PMCPMC4042667

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.